Cineverse Corp. filings document material events, capital-structure actions and governance matters for an entertainment technology company and studio listed on Nasdaq under its Class A common stock. Recent 8-K disclosures cover material agreements, registered equity-offering activity, preferred-stock exchange arrangements, and other transactions affecting the company’s common and preferred securities.
The company’s regulatory record also includes disclosures on executive officer changes, employment arrangements, equity incentive plan amendments, annual meeting votes and acquisition-related material events. These filings provide formal reporting on Cineverse’s governance, shareholder approvals, security structure and corporate actions alongside its operating and financial-result disclosure categories.
Cineverse Corp. (CNVS) filed Amendment No. 2 to its 2025 proxy, updating Proposal Four language about the 2017 Equity Incentive Plan. The plan now states a $1,000,000 annual cap on the aggregate value of Common Stock issuable to all non-employee directors. It also clarifies that each non-employee director is anticipated to receive a $90,000 restricted stock award after each annual meeting, valued using the trailing 20-day VWAP as of the meeting date, whether or not the proposal is approved.
Cineverse Corp. (CNVS) filed definitive additional proxy materials tied to its 2025 annual meeting set for November 20, 2025. The filing states it was made solely to include required interactive data; all other proxy details remain unchanged.
Stockholders will vote on electing four directors, an advisory say‑on‑pay, the frequency of future say‑on‑pay (the Board recommends 1 year), an amendment to the 2017 Equity Incentive Plan to increase authorized shares from 2,504,913 to 3,504,913, and ratification of EisnerAmper LLP as auditor for the year ending March 31, 2026.
Holders of record on September 24, 2025 may vote. 19,124,406 shares of Class A Common Stock were outstanding as of that date. The proxy outlines plan governance features (no evergreen, no repricing without stockholder approval, minimum one‑year vesting, clawback) and indicates non‑employee director equity awards valued at $90,000 annually (based on 20‑day VWAP) and $180,000 for new directors. CNVS last closed at $3.50 on September 24, 2025.
Mark W. Lindsey, Chief Financial Officer of Cineverse Corp. (CNVS) reported changes in his holdings on 10/08/2025. The filing shows a disposition of 119,168 shares of Class A common stock, leaving him with several categories of equity awards: outstanding stock appreciation rights exercisable at $11.95 covering 20,000 underlying shares, and multiple restricted stock units (RSUs) and a separate RSU grant that together total 209,175 underlying Class A shares across different vesting schedules. One RSU tranche of 70,809 shares was reported as acquired on 10/08/2025 at $0 (i.e., newly granted).
The disclosure itemizes vesting timelines: portions of RSUs vest in 2026, 2027, and 2028, and SAR vesting dates include 11/14/2023 through 11/14/2025. The mix of a cashless/zero-price grant and multi-year vesting schedules indicates continued equity compensation tied to future service.
Insider transfer reported by Cineverse Corp. officer Yolanda Macias. The filing shows Ms. Macias holds 93,949 Class A shares indirectly and reports a disposition of 93,949 Class A shares plus an indirect 146 share holding for a minor child. She also holds multiple equity awards: two stock appreciation rights covering 30,000 and 25,000 shares with exercise prices of $12.8 and $5.8, and restricted stock units (RSUs) totaling 305,253 underlying Class A shares across several grants. A grant of 79,879 RSUs was reported as acquired on 10/08/2025 with $0 price; portions of RSUs vest annually through 10/08/2028 and other grants vest through 05/01/2028 and 04/25/2027.
Christopher J. McGurk, CEO and Chairman of Cineverse Corp. (CNVS), reported changes in his beneficial ownership on 10/08/2025. He acquired 263,006 restricted stock units (RSUs) that convert one-for-one into Class A common stock and now directly holds 263,006 shares from that grant. The filing also shows 103,526 Class A shares held indirectly via the Christopher and Jamie McGurk Living Trust and a reported disposition of 492,519 Class A shares. McGurk retains multiple stock appreciation rights and prior RSUs/awards: 35,000, 125,000, and 125,000 SARs at exercise prices of $29.4, $10.8, and $9.6 respectively, plus outstanding RSUs totaling 220,000 that vest on scheduled future dates. Vesting schedules for the awards are disclosed through 10/08/2028.
Insider transaction summary for Cineverse Corp. (CNVS): The reporting officer, Mark Antonio Huidor, reported a disposal and several derivative/award holdings. On 10/08/2025 he disposed of 152,561 shares of Class A common stock. Following that transaction his direct holdings include vested and unvested equity awards: a $5.8 strike stock appreciation right exercisable into 50,000 shares, and multiple restricted stock units (RSUs) and other awards totaling 382,746 Class A shares equivalent (sum of listed amounts). A newly acquired grant of 121,792 RSUs was recorded with $0 per-share price and vesting scheduled across 2026–2028. The filing shows staged vesting dates for existing awards.
Cineverse Corp. (CNVS) reported an insider equity award on a Form 4. The company’s Chief People Officer received 66,763 restricted stock units (RSUs) on 10/08/2025 (transaction code A, price $0). These RSUs vest in three equal-year tranches: 22,254 on October 8, 2026, 22,254 on October 8, 2027, and 22,255 on October 8, 2028.
Following the reported transactions, the officer beneficially owned 158,274 shares of Class A common stock directly. Derivative holdings include stock appreciation rights for 8,334 shares (exercise price $39.4, expiring 02/17/2031) and 12,500 shares (exercise price $5.8, expiring 05/16/2033), plus other RSUs of 66,667 and 76,820 with stated vesting schedules.
Erick Opeka, CSO and President of Cineverse Corp. (CNVS), reported multiple equity changes on 10/08/2025. The filing shows a disposition of 194,146 shares of Class A common stock and the acquisition/vesting of 144,147 restricted stock units into Class A common stock at no cash cost. The report lists outstanding stock appreciation rights with strike prices of $23.2, $12.8, and $5.8 covering 17,750, 60,000, and 75,000 underlying shares respectively. Several previously granted restricted stock units and appreciation rights have scheduled vesting dates between 2024 and 2028, with specific RSU tranches vesting in 2026, 2027, and 2028.
Gary S. Loffredo, Chief Legal Officer, Secretary and Senior Advisor at Cineverse Corp. (CNVS), filed a Form 4 reporting multiple equity changes on 10/08/2025. The filing shows a disposition of 170,337 shares of Class A common stock and the grant or settlement of 130,289 restricted stock units (RSUs) that were reported as acquired at $0. In addition, the filing lists existing stock appreciation rights (SARs) and RSUs totaling 203,867 underlying Class A shares across several award tranches with exercise prices of $29.4, $12.8 and $5.8 and multiple staggered vesting schedules through 2033. The document clarifies vesting timetables for legacy SARs and newly reported RSUs, indicating staged vesting dates in 2026, 2027 and 2028.
Cineverse Corp. outlines its 2017 Equity Incentive Plan governance and 2023–2025 executive and director compensation practices. The plan is administered by an independent Compensation Committee, has no evergreen replenishment, and caps aggregate director awards at 300,000 shares. Awards generally carry a minimum one-year vesting requirement (with a 5% exception), prohibit discounted options or repricings without stockholder approval, and are subject to the company's clawback policy.
Reported grants include 237,500 restricted stock awards and 237,500 restricted stock units to NEOs in fiscal 2025 (accounting for $1,501,000 of NEO CAP), and 150,000 restricted awards and 150,000 restricted units to the PEO in fiscal 2025 (accounting for $948,000 of the PEO CAP). Prior-year grants included 115,000 options in 2024 and 125,000 options in 2023 with multi-year vesting and ten-year option terms where noted. Non-employee director pay includes a $60,000 cash retainer, a $90,000 annual stock grant (trailing 20-day VWAP), committee fees, a $20,000 lead director fee, and a $180,000 new-director grant vesting over three years.